t(4;20)(q12;p13)
2023-07-13 Lisa Ximena Rodriguez, PhD , Jorge Andres Olave Rodriguez , Juan José Albán Silva Affiliation1.Fundacion Valle del Lili
Abstract
A 50-year-old patient diagnosed with chronic myeloid leukemia at the age of 50, resistant to treatment with imatinib, dasatinib, and nilotinib. Currently undergoing treatment with ponatinib, with persistent hematological abnormalities (leukocytosis and thrombocytosis). The latest flow cytometry analysis shows 3.8% myeloid blasts, and the karyotype analysis reveals an additional t(4;20) chromosomal translocation in addition to BCR-ABL, which had not been previously observed in the same patient.
Keywords
Chronic myeloid leukaemia,BCR-ABL positive,ResistantClinics and Pathology
Disease
chronic myeloid leukemia
Clinics
A 50-year-old patient diagnosed with chronic myeloid leukemia at the age of 50, resistant to treatment with imatinib, dasatinib, and nilotinib. Currently undergoing treatment with ponatinib, with persistent hematological abnormalities (leukocytosis and thrombocytosis). The latest flow cytometry analysis shows 3.8% myeloid blasts, and the karyotype analysis reveals an additional t(4;20) chromosomal translocation in addition to BCR-ABL, which had not been previously observed in the same patient.
Phenotype
Immunophenotypic study of bone marrow revealing 3.8% myeloid blasts accompanied by an increase in basophils. The other evaluated cell populations show no abnormalities. Viability: 81.4%. Events: 1,000,000.
Evolution
There is no response to the treatment.
Cytogenetics
Cytogenetics morphological
Bibliography
No bibliography items were found for this article.
Citation
Lisa Ximena Rodriguez, PhD ; Jorge Andres Olave Rodriguez ; Juan José Albán Silva
t(4;20)(q12;p13)
Atlas Genet Cytogenet Oncol Haematol. 2023-07-13
Online version: http://atlasgeneticsoncology.org/haematological/209191/files/1689274964_t4;20.jpg
